199 related articles for article (PubMed ID: 28956336)
1. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Padovan-Neto FE; West AR
Adv Neurobiol; 2017; 17():257-283. PubMed ID: 28956336
[TBL] [Abstract][Full Text] [Related]
2. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
[TBL] [Abstract][Full Text] [Related]
3. Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.
Threlfell S; West AR
Basal Ganglia; 2013 Dec; 3(3):137-146. PubMed ID: 24490129
[TBL] [Abstract][Full Text] [Related]
4. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.
Threlfell S; Sammut S; Menniti FS; Schmidt CJ; West AR
J Pharmacol Exp Ther; 2009 Mar; 328(3):785-95. PubMed ID: 19056933
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.
Padovan-Neto FE; Sammut S; Chakroborty S; Dec AM; Threlfell S; Campbell PW; Mudrakola V; Harms JF; Schmidt CJ; West AR
J Neurosci; 2015 Apr; 35(14):5781-91. PubMed ID: 25855188
[TBL] [Abstract][Full Text] [Related]
8. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
9. Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?
Nthenge-Ngumbau DN; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):822-834. PubMed ID: 28062949
[TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Kelly MP
Cell Signal; 2018 Jan; 42():281-291. PubMed ID: 29175000
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Sancesario G; Morrone LA; D'Angelo V; Castelli V; Ferrazzoli D; Sica F; Martorana A; Sorge R; Cavaliere F; Bernardi G; Giorgi M
Neurochem Int; 2014 Dec; 79():44-56. PubMed ID: 25452081
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
14. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Sharma VK; Singh TG; Singh S
Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterases in neurodegenerative disorders.
Bollen E; Prickaerts J
IUBMB Life; 2012 Dec; 64(12):965-70. PubMed ID: 23129425
[TBL] [Abstract][Full Text] [Related]
16. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.
Wennogle LP; Hoxie H; Peng Y; Hendrick JP
Adv Neurobiol; 2017; 17():349-384. PubMed ID: 28956339
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Santini E; Alcacer C; Cacciatore S; Heiman M; Hervé D; Greengard P; Girault JA; Valjent E; Fisone G
J Neurochem; 2009 Feb; 108(3):621-33. PubMed ID: 19187092
[TBL] [Abstract][Full Text] [Related]
19. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
